{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-055666","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.358529+00:00","generated_at":"2026-05-24T17:10:53.766701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"XOMA Royalty reports Q4/FY2024 revenue $28.5M, net loss $13.8M; portfolio doubled to 120+ assets","bullets":["Total revenue $8.7M Q4, $28.5M FY2024 (vs $1.8M and $4.8M in 2023); net loss $4.0M Q4, $13.8M FY2024.","Cash and equivalents $106.4M at Dec 31, 2024; cash receipts totaled $46.3M in FY2024.","Doubled royalty portfolio to over 120 assets via five 2024 transactions: Twist ($15M), Daré ($22M), Talphera ($8M), Kinnate ($2.5879/sh + CVR), Pulmokine ($20M).","FDA approvals for Day One's OJEMDA and Zevra's MIPLYFFA; milestone payments received from both.","Non-cash credit losses $30.9M FY2024 (Agenus, Aronora, Talphera); management sees path to cash flow positive from royalties alone in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-055666","json":"https://secwatch.observer/filing/0001193125-25-055666.json","markdown":"https://secwatch.observer/filing/0001193125-25-055666.md","text":"https://secwatch.observer/filing/0001193125-25-055666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312525055666/0001193125-25-055666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312525055666/d903231d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T17:10:53.766701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}